Hospital Clínico Universitario Lozano Blesa -ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

    Disease markers, Vol. 2022, pp. 3132941

2021

  1. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

    Scientific Reports, Vol. 11, Núm. 1